Metabolic & Cardiometabolic
stopping GLP-1 receptor agonists causes substantial weight regain
In plain terms: If I stop a GLP-1 drug, will I gain the weight back?
Strong support Metabolic & Cardiometabolic 🔬 Includes disconfirming
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 0.88
Yes — trials and pooled data consistently show people regain about two-thirds of lost weight within ~1 year of stopping, so these drugs work like chronic therapy rather than a cure.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
13 support 0 contradict 1 tested null 3 mixed · 17 sources, 13 independent groups · 3 superseded — pooled inside a review, counted once
The evidence (20)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Kolli RT et al 2025 · study_type: meta-analysis | meta-analysis | supports | moderate | Meta-analysis of 36 studies (PubMed/Cochrane/Scopus/ScienceDirect/Web of Science, Jan 2010-Oct 2024) quantifying weight regain after peak weight loss: semaglutide MD=-5.15kg, exenatide -3.06kg, liraglutide -1.50kg, orlistat -1.66kg after di |
| Wilding 2022 · Diabetes Obes Metab | RCT | supports | moderate | STEP-1 extension: after withdrawal, semaglutide group regained 11.6 of 17.3 percentage-pts lost by wk120 (~two-thirds); BP/lipids reverted too. ↩ SUPERSEDED — pooled in the review above, counted once |
| Wilding 2021 · N Engl J Med | RCT | supports | high | STEP-1 main trial establishes the ~14.9% on-drug loss that is largely reversed on withdrawal (baseline for extension regain). ↩ SUPERSEDED — pooled in the review above, counted once |
| Lau D et al] # corrected 2026-08-17 from PubMed; was [Rubino 2021 · Ann Intern Med | RCT | supports | moderate | Synopsis of STEP-4: continued semaglutide maintained loss while withdrawal produced regain; corroborates primary. |
| Khanna A et al 2026 · study_type: observational | observational | supports | low | Review of STEP 1-5 trials: STEP 4 highlighted notable weight regain following treatment withdrawal ('reflecting the relapsing nature of obesity'); STEP 5 confirmed maintenance of ~15% loss with continued treatment over 2 years. No specific |
| Yates N et al 2025 · study_type: observational | observational | supports | low | Narrative review/prescriber guide states regaining weight is common when GLP-1/GIP drugs are stopped, hence usually need long-term continuation. No quantitative regain data given. |
| Amorim 2026 · Chronic Dis Transl Med | observational | mixed | low | Review flags durability/duration as key gap; benefits wane without continued GLP-1RA exposure. |
| Damen 2026 · Ann Intern Med | meta-analysis | supports | high | Living network MA for ACP notes weight benefits of obesity pharmacotherapy are not durable after discontinuation. |
| Berg 2025 · Obes Rev | meta-analysis | supports | high | SR/MA (n=2372): after stopping, regain proportional to loss — liraglutide +2.20kg, semaglutide/tirzepatide +9.69kg; regardless of lifestyle. |
| Aronne 2024 · JAMA | RCT | supports | high | SURMOUNT-4: stopping tirzepatide gave +14.0% vs -5.5% continued (difference 19.4 pts); only 16.6% of placebo kept >=80% loss. |
| Tzang CC et al 2025 · study_type: meta-analysis | meta-analysis | supports | high | Systematic review and meta-analysis of 18 RCTs (3771 participants, PROSPERO-registered): in obesity, GLP-1RA discontinuation caused body weight gain of 5.63kg (95% CI 3.52-7.73) and HbA1c rise of 0.25%; in T2D, weight gain 2.03kg. Greater r |
| Budini B et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Systematic review + nonlinear meta-regression of 48 studies (6 RCTs, n=3236 in the pooled model): at 1 year post-cessation 60% of lost weight was regained, plateauing at an estimated 75.3% (95% CI 68.9-81.6) of weight lost. |
| Ritsinger 2026 · Diabetes Obes Metab | observational | mixed | moderate | Real-world context: sustained risk reduction presupposes sustained treatment/weight control, undermined by discontinuation. |
| Lasik L et al 2026 · study_type: observational | observational | supports | low | Narrative review: clinical trial data indicate GLP-1/GIP cessation is associated with biologically driven weight regain and partial loss of metabolic benefits, attributed to adaptive thermogenesis and hunger-satiety axis changes. No new qua |
| McGowan 2025 · Nat Med | meta-analysis | supports | high | SR/MA of obesity pharmacotherapy: maximal weight loss is treatment-duration dependent; cessation reverses gains. |
| Kramer 2024 · J Clin Endocrinol Metab | observational | mixed | moderate | GLP-1RA after bariatric surgery: weight trajectory depends on continued treatment; supports chronic-therapy framing. |
| Rubino 2021 · JAMA | RCT | supports | high | STEP-4 withdrawal: switching to placebo at wk20 led to +6.9% regain vs -7.9% with continued semaglutide (difference ~14.8 pts). ↩ SUPERSEDED — pooled in the review above, counted once |
| Quarenghi M et al 2025 · study_type: observational | observational | supports | moderate | Narrative review of 13 RCTs (search of PubMed/Cochrane/Google Scholar) found rapid regain of weight after cessation of liraglutide, semaglutide, or tirzepatide regardless of treatment duration, substantially mitigating metabolic benefits. |
| Codella R et al 2025 · study_type: observational | observational | supports | low | Narrative review states stopping GLP-1 therapy alone often leads to weight regain, contrasted with exercise-supported maintenance. No specific n or % regain reported. |
| Hamarsheh 2026 · Endocrinol Diabetes Metab | meta-analysis | tested-null | low | NMA of anti-obesity drugs: efficacy is on-treatment; durability requires ongoing therapy, consistent with regain on stopping. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.